Pramod Thomas is a senior correspondent with Asian Media Group since 2020, bringing 19 years of journalism experience across business, politics, sports, communities, and international relations. His career spans both traditional and digital media platforms, with eight years specifically focused on digital journalism. This blend of experience positions him well to navigate the evolving media landscape and deliver content across various formats. He has worked with national and international media organisations, giving him a broad perspective on global news trends and reporting standards.
JOE ROOT said he had lost none of his desire to score runs for his country and get better as a player after compiling his 34th test century on Saturday (31) at Lord's in the second test against Sri Lanka.
Root's second hundred of the match put his team in a strong position to clinch the series and took him to the top of the list of England test centurions.
"I feel like there's a lot more work to be done and a lot more to contribute still," Root told reporters.
"As a player you pride yourself on affecting games and trying to contribute to winning causes, and the last few years I've obviously had a good time of it.
"You've just got to keep putting the work in and trying to continue doing that and adding to what is a really exciting team," he said.
Root attributed part of his success to the more swashbuckling approach the team have adopted under coach Brendon McCullum and regular captain Ben Stokes.
"The way we look at the game now is so fun to be around, to be a part of, and it's an environment where you see guys come in and thrive. And even as a senior player that gives you so much energy and you continue wanting to add and evolve and get better," he said.
"Teams have got so much knowledge and information now that you can't be happy with where you're at, and you can't be expecting to play the same way all the time."
Root added that it was important to have the time to improve your game.
"The last little while, I feel like I've had a good balance of wanting to get better and evolving, but not trying too much too quickly - I guess that's the art of it," he said.
Joe Root acknowledges the crowd as he walks back to the pavilion . Action Images via Reuters/Andrew Boyers
Root, who made 143 in the first innings to move level with the previous England record of 33 hundreds held by the retired Alastair Cook, went to a century on Saturday's third day when he cut Lahiru Kumara for the 10th four off 111 balls faced.
It meant Root surpassed his fellow former England captain's mark. It is Root's 145th Test compared to Cook's career tally of 161 matches.
Root's seventh Test hundred at Lord's also gave him sole possession of the record for the most Test centuries at the 'Home of Cricket' he had shared with the England duo of Graham Gooch and Michael Vaughan, who both managed six apiece.
Root also became the fourth batsman to have scored hundreds in both innings of a Test at Lord's, joining the West Indies' George Headley (1939), Gooch (1990) and Vaughan (2004).
Root's latest century also moved him into joint-sixth place in an all-time list of Test century-makers headed by India great Sachin Tendulkar, who scored 51 hundreds in 200 Tests from 1989-2013.
The 33-year-old Root is the only batsman in this group who is still an active Test cricketer.
Most Test hundreds (number of hundreds, matches, player, team (s), span):
51 200 Sachin Tendulkar IND 1989-2013
45 166 Jacques Kallis RSA 1995-2013
41 168 Ricky Ponting AUS 1995-2012
38 134 Kumar Sangakkara SRI 2000-2015
36 164 Rahul Dravid IND/ICC 1996-2012
34 118 Younis Khan PAK 2000-2017
34 125 Sunil Gavaskar IND 1971-1987
34 131 Brian Lara WIS/ICC 1990-2006
34 149 Mahela Jayawardene SRI 1997-2014
34 145 Joe Root ENG 2012 -
33 161 Alastair Cook ENG 2006-2018
Hundreds in both innings of a Test at Lord's (scores, player, team, opposition, year):
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.